Stryker Corporation
Rank #189Capital ReturnSYK · NYSE · Healthcare
Stryker Corporation (SYK) — Rank #189 by gross profitability (GP/assets 0.34) · ROE 13.5% · Piotroski F-Score 4 / 9.
As-of 2026-09-15 · CIK 0000310764 · all metrics point-in-time as of the filing date.
About
Stryker Corporation operates as a medical technology company in the United States and internationally.
Show moreShow less
It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries.
Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- MI
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- stryker.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-11 | 2024-12-31filed 2025-02-12 | 2023-12-31filed 2024-02-14 | 2022-12-31filed 2023-02-10 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 1,570.0 | 1,426.0 | 1,341.0 | 1,278.0 |
| Stock-based compensation | 243.0 | 229.0 | 205.0 | 168.0 |
| Change in receivables | (127.0) | 321.0 | 175.0 | 579.0 |
| Change in inventory | 297.0 | 206.0 | 797.0 | 762.0 |
| Operating cash flow | 5,044.0 | 4,242.0 | 3,711.0 | 2,624.0 |
| Investing | ||||
| Capital expenditures | 761.0 | 755.0 | 575.0 | 588.0 |
| Acquisitions, net of cash | 4,960.0 | 1,628.0 | 390.0 | 2,563.0 |
| Investing cash flow | (4,866.0) | (3,000.0) | (962.0) | (2,924.0) |
| Financing | ||||
| Debt issued | 2,979.0 | 3,011.0 | 1,241.0 | 1,500.0 |
| Debt repaid | 1,400.0 | 2,039.0 | 2,058.0 | 653.0 |
| Share repurchases | — | — | — | — |
| Dividends paid | 1,284.0 | 1,219.0 | 1,139.0 | 1,051.0 |
| Financing cash flow | 113.0 | (525.0) | (1,594.0) | (749.0) |
| Summary | ||||
| Free cash flow | 4,283.0 | 3,487.0 | 3,136.0 | 2,036.0 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?